GeoVax Highlights Need for Domestic Vaccine Manufacturing Amid Global Outbreaks

As global health threats escalate, GeoVax Labs, Inc. (Nasdaq: GOVX) is spotlighting the urgent need for diversified vaccine supply and scalable U.S.-based manufacturing. The World Health Organization’s declaration of a Public Health Emergency of International Concern for the ongoing Ebola outbreak involving the Bundibugyo strain, alongside the continued international spread of Clade I mpox and recent hantavirus concerns, underscores the dynamic nature of biodefense. GeoVax CEO David A. Dodd emphasized that these events reinforce the importance of flexible vaccine preparedness infrastructure. GeoVax’s primary focus is GEO-MVA, a Modified Vaccinia Ankara (MVA) mpox and smallpox vaccine candidate, which aligns with the growing global emphasis on diversified supply and domestic manufacturing.

GeoVax recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway for GEO-MVA, with a pivotal trial scheduled to begin in Q4 2026 and data expected by mid-2027. The company believes its MVA platform has broader applicability, as demonstrated by prior preclinical studies where an MVA-based Ebola-Zaire vaccine candidate provided complete protection in non-human primate lethal-challenge studies. The company advocates for long-term investment in rapid-response platform technologies and domestic manufacturing capabilities to strengthen biodefense readiness beyond individual outbreak cycles.

GeoVax also highlighted that the MVA platform's versatility extends to other infectious diseases, reinforcing the strategic importance of scalable manufacturing. With recent global developments, the company sees a clear imperative for proactive preparedness infrastructure. For more details, visit www.geovax.com.